Equine Injectable Anesthesia Requires a 100 mg/mL Ketamine Base Formulation with Tight Endotoxin Control

Ketamine HCl veterinary-grade API, the active entity of reference listed drug Ketalar, is supplied as a white crystalline powder with a salt-to-base conversion factor of 1.1534 because the molecular masses are 274.19 g/mol for the HCl salt and 237.72 g/mol for the free base. Manufacture of a 100.0 mg/mL base-equivalent injection therefore begins by dissolving 115.34 mg/mL of ketamine HCl (11.53% w/v) in water for injection at 20–25 °C inside a 316L stainless steel jacketed vessel fitted with a bottom-mounted magnetic stirrer operating at 150–200 rpm. Dissolution time at production scale lengthens from 12 min to 28 min when incoming API D90 exceeds 150 µm, a batch-to-batch variance documented in technical transfer reports. Benzethonium chloride 0.10 mg/mL is added as a multidose preservative, the solution is sparged with filtered nitrogen, and pH is adjusted to 5.0–6.5 with 1 N hydrochloric acid or sodium hydroxide. The bulk solution is passed through a 0.45 µm polypropylene prefilter and then a 0.22 µm PVDF sterilizing-grade membrane; a differential pressure above 0.8 bar at 25 °C signals prefilter fouling and requires interruption. Aseptic filling is performed under EU GMP Annex 1 Grade A conditions with an ISO 7 background. Release testing includes USP <71> sterility, USP <85> bacterial endotoxin with a typical release limit of 0.50 EU/mg for intravenous products, USP <788> particulate matter, and 21 CFR 522.1222 conformance where the dosage form enters the US veterinary supply chain. Terminal products are 10 mL, 20 mL, and 50 mL multidose vials at 100.0 mg/mL base, plus 10 mg/mL and 50 mg/mL single-dose vials for small species and ambulatory protocols. The free base has a pKa of approximately 7.5; mixing with alkaline injectable barbiturates or solutions above pH 8.0 produces precipitation of the lipophilic base, and terminal steam sterilization at 121 °C is avoided because of hydrolytic degradation, leaving aseptic filtration as the controlling unit operation. For food-producing species, the destination market must be checked because extralabel use is prohibited in some jurisdictions.

A 1.0 mg/mL constant-rate infusion premix for feline and canine perioperative analgesia is prepared by aseptically transferring 10.0 mL of a 100.0 mg/mL ketamine base injection into 990 mL of 0.9% sodium chloride or lactated Ringer’s solution in a 500 mL or 1000 mL polyolefin infusion bag, a 1:100 dilution yielding 1000 µg/mL ketamine base. Infusion delivery rates are typically set at 0.2–0.6 mL/kg/h, corresponding to 0.2–0.6 mg/kg/h ketamine base, via a syringe pump or volumetric pump. Compounding is performed in an ISO 7 cleanroom under USP <797> low-risk sterile preparation standards, with direct aseptic transfer and sterile closed-system devices to reduce touch contamination. Terminal forms are 250 mL, 500 mL, and 1000 mL premix bags or elastomeric infusors labeled with beyond-use dating not exceeding 24 h at 2–8 °C unless site-specific stability studies justify extension. The regulatory framework is 21 CFR 530 AMDUCA for extralabel veterinary use; controlled substance storage and recordkeeping follow 21 CFR 1301.71. A known production bottleneck is gravimetric verification of the transferred active volume: for batches above 20 bags, gravimetric confirmation is more reproducible than volumetric transfer. A formulation boundary is that published stability data for lactated Ringer’s dilutions beyond 24 h is limited; pH shifts above 6.5 increase free-base proportion, and at pH above 7.5 visible precipitation may occur.

What Low-Tensile-Force Direct Compression Does to Ketamine HCl Granule Capping

Ketamine HCl API is a cohesive, crystalline powder with poor flow, so direct compression into veterinary tablets requires dry granulation—roller compaction or slugging—to produce dense granules with a D50 between 150 µm and 300 µm. A representative 50.0 mg tablet formula in the non-sterile compounding sector is presented below. The ketamine HCl mass fraction is 34.5% w/w, with microcrystalline cellulose PH102 60.0% w/w, crospovidone 4.1% w/w, colloidal silicon dioxide 0.7% w/w, and magnesium stearate 0.7% w/w for a total tablet mass of 145.0 mg. In a 12-station rotary tablet press, pre-compression force is set at 3 kN and main compression force at 8–12 kN. Capping is observed when magnesium stearate is blended longer than 5 min or when granule moisture exceeds 3.0%; the resulting tablets fail friability testing before hardness reaches 4 kp. Because no USP monograph exists for ketamine HCl tablets, release testing is derived from in-house validated methods for assay and dosage-unit uniformity under USP <905>, with non-sterile preparation standards governed by USP <795>. Extralabel veterinary use falls under 21 CFR 530, and controlled substance inventory requirements follow 21 CFR 1301.74. Terminal products are 25 mg, 50 mg, and 100 mg tablets for cats, dogs, and approved laboratory animals. Published clinical data for oral ketamine HCl tablets in veterinary species is limited; oral dosing is subject to extensive first-pass metabolism to norketamine, so dose selection requires veterinary observation rather than simple intravenous-equivalent scaling.

Capsule compounding for feline neuropathic pain and canine multimodal analgesia uses ketamine HCl powder triturated with microcrystalline cellulose and colloidal silicon dioxide before encapsulation. A representative size 4 hard gelatin capsule contains 10.0 mg ketamine HCl (10.0% w/w), 89.0 mg microcrystalline cellulose (89.0% w/w), and 1.0 mg colloidal silicon dioxide (1.0% w/w); a 25 mg strength requires a size 3 capsule with the same geometric-dilution sequence. Microcrystalline cellulose is preferred over lactose in feline formulations because lactase insufficiency can complicate lactose-containing excipients. Blending is performed in a V-blender at 25 rpm for 10 min, after both API and fillers are passed through a 60-mesh stainless steel sieve. Encapsulation on a semiautomatic dosator capsule machine operates at 40–60 cycles/min with average fill-weight variation controlled to ±5% and in-process checks every 15 min. The finished capsules are governed by USP <795> for non-sterile preparations, 21 CFR 530 for veterinary extralabel use, and 21 CFR 1301.74 for controlled substance inventory records. Terminal products are 5 mg, 10 mg, 25 mg, and 50 mg capsules for feline, canine, and limited exotic species patients. A known oral-route boundary is that published oral bioavailability in dogs is below 0.5 where measured; the drug undergoes substantial first-pass conversion to norketamine, so plasma concentrations do not correlate directly with intravenous-equivalent dose calculations. For this configuration, published data for repeated-dose efficacy is limited, and field use depends on clinician-compounded prescriptions with individualized patient monitoring.

When Aseptic Lyophilization Replaces Ready-to-Use Solution in Remote Veterinary Posts

For remote or ambulatory veterinary operations where liquid weight and cold-chain stability are limiting, sterile ketamine HCl lyophilized powder offers a reconstituted injectable route. The pre-lyophilization solution is prepared at 50.0 mg/mL ketamine base with 2.5% w/v mannitol as bulking and cryoprotectant in water for injection; a 10.0 mL fill into a 20 mL Type I glass vial yields a 500 mg dry cake. Freeze-drying parameters include a freezing ramp to −40 °C, primary drying at −20 °C shelf temperature under 0.2 mbar vacuum, and secondary drying at 20 °C until residual moisture is below 1.0% by Karl Fischer titration. Aseptic production is governed by EU GMP Annex 1, with release testing under USP <71>, USP <85>, and USP <921> for moisture determination. Terminal products are 250 mg and 500 mg single-vial units that yield 50.0 mg/mL solution after reconstitution with 5.0 mL or 10.0 mL WFI; reconstituted solutions are for immediate use with beyond-use dating of 6 h at 20–25 °C or 24 h at 2–8 °C unless extended by site-specific stability data. A process failure mode observed on production-scale freeze-driers is collapsed cake above 1.0% residual moisture, which increases reconstitution time beyond 120 s at 20 °C and indicates a failed lyophilization cycle. Published data for ketamine HCl lyophilization at production scale is limited; cycles are generally transferred from small-scale thermal characterization studies, so each new vial size requires re-qualification of primary drying pressure and shelf temperature.

Bulk Powder Flowability for Non-Sterile Veterinary Oral Suspension Compounding

Ketamine HCl API in powder or granulated form is incorporated into oral suspension vehicles for laboratory animal protocols and specialized exotic-species administration when intravenous access is unavailable. A representative 20.0 mg/mL suspension is prepared by levigating 2.0 g ketamine HCl in 5.0 mL glycerin, then gradually adding a 1:1 mixture of Ora-Plus and Ora-Sweet to a final volume of 100 mL; the active concentration is 2.0% w/v. High-shear dispersion at 2000 rpm for 3–5 min using an overhead mixer fitted with a 40 mm dispersing blade reduces aggregate size; the suspension is then passed through a 60-mesh screen before transfer into amber glass or PET bottles. The governing standard is USP <795> for non-sterile compounding, with cleaning validation linked to USP <1163> quality assurance in pharmaceutical compounding. Terminal products are 10 mL, 30 mL, and 100 mL oral suspensions at 10 mg/mL or 20 mg/mL, used in laboratory rodents, rabbits, ferrets, and select avian patients under institutional animal care committee approval. Raw ketamine HCl powder presents a production bottleneck: bulk density is typically below 0.45 g/cm³ and Carr index above 30, so granulated grades are preferred when automated powder dispensing is used. Controlled substance obligations include 21 CFR 1301.71 storage security and 21 CFR 530 extralabel veterinary use. No feed-premix application is recognized because ketamine is not approved as a feed additive and would pose diversion and environmental contamination risk.